Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> reported 1H26 revenue of $477M, up 22% YoY, driven by Precision Medicine, tracking in line with the upper end of full year guidance of $950–970M.</li>
<li>Pixclara, an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer), has been granted a PDUFA goal date by the FDA of September 11, 2026.</li>
<li>With two‑product PSMA imaging strategy (Illuccix and Gozellix) differentiated clinical positioning, and expanding commercial presence globally, Telix is well-positioned for continued growth.</li>
</ul>



Telix Pharmaceuticals (TLX AU) reported 1H26 revenue of $477M, up 22% YoY, driven by Precision Medicine, tracking in line with the upper end of full year guidance of $950–970M.
Pixclara, an investigational PET imaging agent for the characterization of recurrent or progressive glioma (brain cancer), has been granted a PDUFA goal date by the FDA of September 11, 2026.
With two‑product PSMA imaging strategy (Illuccix and Gozellix) differentiated clinical positioning, and expanding commercial presence globally, Telix is well-positioned for continued growth.


Telix Pharmaceuticals (TLX AU): Stellar H1 Financial Performance; Eye on Upcoming Approval

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul><li>Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress PSMA imaging continues to gain market share Higher R&D spending accelerates pipeline development Regulatory catalysts could drive the next re-rating</li></ul>

Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress PSMA imaging continues to gain market share Higher R&D spending accelerates pipeline development Regulatory catalysts could drive the next re-rating

Strong Result, Can Telix Continue To Deliver?

Thematic (Sector/Industry)

<ul>
<li>Hansoh Pharmaceutical’s risvutatug rezetecan has been included in the Priority Review and Approval Procedure of NMPA. Innocare entered research collaboration and license agreement with Eli Lilly to develop new medicines.</li>
<li>Astellas Pharma initiated Phase 3 trial evaluating setidegrasib for NSCLC. Otsuka announced positive topline results from the Phase 3 trial evaluating ulefnersen in a genetic subtype of amyotrophic lateral sclerosis.</li>
<li>Elevar Therapeutics won FDA approval for Lyrfigtu for bile duct cancer. Telix Pharmaceuticals will acquire ITM Isotope Technologies, a global leader in radioisotope production and radiopharmaceutical development, for $1.65B upfront.</li>
</ul>


Hansoh Pharmaceutical’s risvutatug rezetecan has been included in the Priority Review and Approval Procedure of NMPA. Innocare entered research collaboration and license agreement with Eli Lilly to develop new medicines.
Astellas Pharma initiated Phase 3 trial evaluating setidegrasib for NSCLC. Otsuka announced positive topline results from the Phase 3 trial evaluating ulefnersen in a genetic subtype of amyotrophic lateral sclerosis.
Elevar Therapeutics won FDA approval for Lyrfigtu for bile duct cancer. Telix Pharmaceuticals will acquire ITM Isotope Technologies, a global leader in radioisotope production and radiopharmaceutical development, for $1.65B upfront.


APAC Healthcare Weekly (Sept 27) – Hansoh Pharma, Innocare, Astellas, Otsuka, Telix Pharmaceuticals

<ul>
<li>Sino Biopharmaceutical’s NDA for bispecific ADC, TQB2102, has been accepted by NMPA for breast cancer. CHMP recommended approval of Impact Therapeutics’ Sepalna for epithelial ovarian, fallopian tube, and peritoneal cancers.</li>
<li>FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque psoriasis. Daiichi Sankyo announced positive results from the Phase 3 trial evaluating Enhertu as a first-line treatment of NSCLC.</li>
<li>SK Biopharmaceuticals has signed a license and equity investment agreement with 1ST Biotherapeutics to secure global exclusive development and commercialization rights for a new drug candidate for Parkinson's disease.</li>
</ul>


Sino Biopharmaceutical’s NDA for bispecific ADC, TQB2102, has been accepted by NMPA for breast cancer. CHMP recommended approval of Impact Therapeutics’ Sepalna for epithelial ovarian, fallopian tube, and peritoneal cancers.
FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque psoriasis. Daiichi Sankyo announced positive results from the Phase 3 trial evaluating Enhertu as a first-line treatment of NSCLC.
SK Biopharmaceuticals has signed a license and equity investment agreement with 1ST Biotherapeutics to secure global exclusive development and commercialization rights for a new drug candidate for Parkinson's disease.


APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> shares gained ~14% YTD. Clinical trial update, re-submission of NDA for Pixclara, 2025 revenue achieving guidance, and 2026 guidance for continued double-digit growth drove the rally.</li>
<li>Telix has guided for 2026 revenue of $950–970M, up 18–21% YoY, with pending regulatory approvals providing further upside potential. Precision Medicine revenue is expected to grow ~25% YoY.</li>
<li>2026 is going to be catalyst heavy for Telix, with Zircaix BLA resubmission in the U.S. and NDA resubmission acceptance of Pixclara in the U.S. being the major ones.</li>
</ul>



Telix Pharmaceuticals (TLX AU) shares gained ~14% YTD. Clinical trial update, re-submission of NDA for Pixclara, 2025 revenue achieving guidance, and 2026 guidance for continued double-digit growth drove the rally.
Telix has guided for 2026 revenue of $950–970M, up 18–21% YoY, with pending regulatory approvals providing further upside potential. Precision Medicine revenue is expected to grow ~25% YoY.
2026 is going to be catalyst heavy for Telix, with Zircaix BLA resubmission in the U.S. and NDA resubmission acceptance of Pixclara in the U.S. being the major ones.


Telix Pharmaceuticals (TLX AU): Shares Are Bouncing off Lows; Driving Forces Behind and What’s Next

Australia

Telix Pharmaceuticals Limited operates as a biotechnology company. The Company develops and commercializes molecularly-targeted radiation therapy for the treatment of prostate, renal, and brain cancer. Telix Pharmaceuticals serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Telix Pharmaceuticals (TLX AU)